Clene (CLNN)
Develops CNM-Au8, an investigational oral therapy for ALS and multiple sclerosis.
Something off on this page? Send us feedback.
CNM-Au8 is its principal drug candidate, an oral gold-nanocrystal therapy being developed for ALS and multiple sclerosis. The clinical-stage company has no commercial drug-candidate sales and depends on clinical, regulatory, financing, and third-party execution.
Built around clean-surfaced nanocrystal therapeutics, the pipeline centers on CNM-Au8, an investigational oral gold-nanocrystal therapy. The company is developing it to address mitochondrial function, the NAD pathway, and oxidative stress in neurodegenerative diseases, including ALS and multiple sclerosis.
Research, development, and manufacturing are split between Salt Lake City and North East, Maryland, with clinical work supported by CROs and research collaborators. CNM-Au8 receives substantially all research and development spending, while no commercial drug-candidate sales have been reported.
Progress depends on clinical and regulatory execution, capital for development and commercialization, third-party CRO and vendor performance, intellectual-property protection, and retention of key people. The business remains development-stage, with limited operating history and no material drug-product revenue.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.7M · Total debt $22.3M · Total assets $23.0M · Shareholders' equity −$24.8M
- Revenue
- $90.0K
- Operating income
- −$5.3M
- Net income
- −$13.4M
No dividends on record.
| Institutions | 24.76% | 3.18M shares | |
|---|---|---|---|
| 33 holders · as of Jun 30, 2026 | |||
| Insiders | 34.08% | 4.38M shares | |
| 5 holders · as of Sep 18, 2026 | |||
| Strategic holders | 5.48% | 704.6K shares | |
| 1 holder · as of Aug 21, 2025 | |||
| Other | 35.68% | 4.58M shares | |
| remainder | |||
12.85M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Alison Mosca1Insiderdirector, 10 percent owner | 15.80% | 1.83M | filed Sep 18, 2026 |
Chidozie Ugwumba2Insider10 percent owner | 10.52% | 1.35M | filed May 15, 2026 |
Empery Asset Management, LPInstitution | 7.13% | 916,532 | as of Jun 30, 2026 |
David J. MatlinInsiderdirector | 7.10% | 912,275 | filed Sep 18, 2026 |
General Resonance LLCStrategic10 percent owner | 5.48% | 704,591 | filed Aug 21, 2025 |
- Alison Mosca's transaction reports restate only vehicles that traded; the 2026 ownership statement (1.83M) plus the 198.2K net shares acquired since is used instead.
- Chidozie Ugwumba's transaction reports restate only vehicles that traded; the 2026 ownership statement (1.35M) is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 12, 2026 | Chidozie Ugwumba | 10 percent owner | −73,296 | $6.20 |
| May 11, 2026 | Chidozie Ugwumba | 10 percent owner | −22,177 | $6.75 |
| May 4, 2026 | Chidozie Ugwumba | 10 percent owner | −72,884 | $6.80 |
| May 1, 2026 | Chidozie Ugwumba | 10 percent owner | −5,795 | $6.01 |
| Apr 30, 2026 | Chidozie Ugwumba | 10 percent owner | −5,736 | $6.08 |
- Biogen
QALSODY and a broad MS portfolio cover both target indications
- MediciNova
Late-stage MN-166 programs overlap ALS and progressive MS
- Coya Therapeutics
Investigational COYA 302 targets ALS through Treg modulation
- TG Therapeutics
BRIUMVI competes in the commercial relapsing-MS treatment market
- Immunic
Vidofludimus calcium is in late-stage relapsing and progressive MS development
- Amylyx Pharmaceuticals
Early-stage AMX0114 development targets the ALS treatment setting
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Clene | $4.39 | −3.30% | $58.0M | — | — | 294.5 | +233.3% |
| Biogen | $220.57 | +0.68% | $32.37B | 38.8 | 16.6 | 3.3 | +3.4% |
| MediciNova | $3.19 | −3.21% | $162.4M | — | — | 176.5 | +241.0% |
| Coya Therapeutics | $5.14 | +3.74% | $116.1M | — | — | 14.5 | +35.6% |
| TG Therapeutics | $57.38 | +0.38% | $8.75B | 20.9 | 30.2 | 10.9 | +70.3% |
| Immunic | $10.89 | +0.57% | $147.5M | — | — | — | — |
| Amylyx Pharmaceuticals | $32.44 | +0.15% | $3.60B | — | — | — | — |
| Median | 29.8 | 23.4 | 12.7 | +52.9% |